Abstract: Biologics such as TNF antagonists are a new class of drugs that have greatly improved Rheumatoid Arthritis (RA) treatment. However, for unknown reasons, individual patients with RA respond to one of these drugs but not to others even those targeting the same molecule. Methods to predict response are sorely needed because these drugs are currently selected by trial and error, what is very inefficient and prejudicial for the patient and the healthcare system. Here, we have explored the discovery of protein biomarkers in serum from patients treated with infliximab, one of the major anti-TNF drugs. The study was based in a quantitative proteomics approach using 8-plex iTRAQ labeling. It combined depletion of the most abundant serum proteins, two-dimensional LC fractionation, protein identification and relative quantification with a hybrid Orbitrap mass spectrometer. This approach allowed the identification of 315 proteins of which 237 were confidently quantified with two or more peptides. The detection range covered up to 6 orders of magnitude including multiple proteins at the ng/mL level. A new set of putative biomarkers was identified comprising 14 proteins significantly more abundant in the non-responder patients. The differential proteins were enriched in apolipoproteins, components of the complement system and acute phase reactants. These results show the feasibility of this approach and provide a set of candidates for validation as biomarkers for the classification of RA patients before the beginning of treatment, so that anticipated non-responders could be treated with an alternative drug. Rheumatoid Arthritis (RA) treatment. However, for unknown reasons, individual 3 patients with RA respond to one of these drugs but not to others even those targeting the 4 same molecule. Methods to predict response are sorely needed because these drugs are 5 currently selected by trial and error, what is very inefficient and prejudicial for the 6 patient and the healthcare system. Here, we have explored the discovery of protein 7 biomarkers in serum from patients treated with infliximab, one of the major anti-TNF 8 drugs. The study was based in a quantitative proteomics approach using 8-plex iTRAQ 9 labeling. It combined depletion of the most abundant serum proteins, two-dimensional 10 LC fractionation, protein identification and relative quantification with a hybrid 11
Introduction 1 2
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease of complex 3 etiology comprising genetic and environmental factors that is characterized by 4 inflammation in multiple joints [1] . Left without treatment, it progresses to disability, 5 deformities due to bone erosion and life shortening. RA prevalence is about 1% of the 6 world population. Classical treatments are still commonly used, but they are not 7 sufficiently effective for many patients. In the last decade, new drugs became available 8 in the group of biologics (monoclonal antibodies, soluble receptors or other complex 9 molecules targeting specific players in the disease process). The first that were available 10 for RA treatment were the tumor necrosis factor (TNF) antagonists. Among them, 11 infliximab, a chimeric antibody comprising a human IgG1 constant fraction and a 12 murine variable region targeting membrane and soluble TNF [2] , has become one of the 13 biologics most commonly used in RA. 14 Biologics have greatly improved RA treatment but none of them is effective in 15 all patients. For unknown reasons, about a third of the patients in whom one of these 16 drugs is assayed fail to show significant improvement. These patients can respond to an 17 alternative biologic targeting the same or a different molecule [3] . Currently, clinical or 18 laboratory methods for the prediction of patients response are not available. Therefore, 19 the only approach to select biologics for a particular RA patient is by trial and error . 20 This approach is associated with notable inefficiency and prejudices because 21 responsiveness can only be assessed after three to six months of treatment. During this 22 time, patients suffer uncontrolled disease with the potential of irreversible damage, and 23 the healthcare system expends large amounts in ineffective drugs. Thus, it is necessary 24 to find biomarkers that make possible the identification of non-responder patients in 25 advance, to treat them with an alternative drug from the beginning. Many studies have 26 already tried to identify this type of biomarkers in the genetics, functional genomics, 27 proteomics, autoantibody and clinical fields, but no reproducible and informative 28
findings have yet been reported [4] . 29
Very few proteomic studies have attempted to identify biomarkers for prediction 30 of response to biologics in RA. A couple of studies analyzed selected cytokines or 31 cytokines plus RA autoantibodies showing that some of them were associated with 32 clinical response to the TNF antagonist etanercept [5, 6] . By contrast, not a single 33 cytokine was associated with response to a different biologic, rituximab, in a similar 34 in the ng/mL level, and identifying 14 putative biomarkers for prediction of response to 1 infliximab that are consistent with our knowledge of the disease. Spain) were enrolled in the study. All were naive for any biologics before the start of 16 the enrollment period. Blood was collected into 8 ml Vacuette Z Serum Sep Clot 17
Activator tubes (Greiner Bio-One GmbH, Frickenhausen, Germany) before starting 18 infliximab administration, left to clot at room temperature for 2 hours and then 19 centrifuged at 3000 g for 10 min. The collected serum was aliquoted and stored at -80ºC. 20
Infliximab (Remicade; Centocor Inc., Malvern, PA) was given following the standard 21 dose and administration schedule. Clinical response was determined 6 months after 22 infliximab initiation according with the European League Against Rheumatism 23 (EULAR) criteria based in the Disease Activity Score 28 (DAS28) [25] . Only patients 24 classified as non-responder (NR, n = 4) or good responder (R, n = 4) were compared to 25 increase the chances of finding differences. The intermediate class of moderate 26 responders was excluded. 27
28
Immunoaffinity depletion of high-abundance proteins 29
30
The six most abundant proteins in serum were depleted using the Hu-6 Multiple 31
Affinity Removal System kit (Agilent Technologies, Wilmington, USA) following 32 manufacturer's instructions. Afterwards, the remaining proteins were concentrated usingresulting air-dried pellets were dissolved in 0.5 M triethylammonium bicarbonate 1 (TEAB) pH 8.5 buffer and protein concentration was measured. 2 3
Protein digestion and iTRAQ labeling 4 5
For each sample, 40 µg of protein, at 1 mg/mL in 0.5 M TEAB pH 8.5 and 0.1% 6 SDS, were reduced with 5 mM tris-(2-carboxyethyl) phosphine (TCEP) at 60ºC for 1 7 hour and cysteine-blocked with 10 mM methyl mehanethiosulfonate (MMTS) at RT for 8 10 min. The proteins were then digested with Sequencing Grade Modified trypsin 9 (Promega, Madison, WI, USA) at a trypsin-to-protein ratio of 1:50, at 37ºC for 6 hours. 10
Each digest was labeled at 25ºC for 3 h with one of the 8-plex iTRAQ reagents 11 previously solubilized in 100 µl isopropanol, according to the manufacturer's 12 instruction (AB Sciex, Framingham, MA, USA). The labeling reactions were stopped 13 by adding phosphoric acid to reach pH below 4.0, and all iTRAQ-labeled samples were 14 combined into one tube. Tryptic peptides were then dried by centrifugal evaporation. pump (1100-series, Agilent Technologies). Dried peptides were reconstituted in 600 µl 21 buffer A, the pH was adjusted to 2.7 with H 3 PO 4 . The flow rate was kept at 0.2 ml/min, 22 and the sample was fractionated using a two-buffer system (buffer A, 7mM KH 2 PO 4 in 23 25% ACN pH 2.7; buffer B 7mM KH 2 PO 4 , 500 mM KCl in 25% ACN pH 2.7). The 24 gradient employed was 0% B for 20 min, 0% to 5% B in 5 min, 5% to 35% B in 35 min, 25 35% to 100% B in 10 min, 100% B for 5 min, and then 0% B for 25 min. (1-3ppm) LTQ MS/MS, and ID focus on biological modification. Proteins having at 33 least one peptide above the 95% confidence level as determined by Protein Pilot wererecorded. False discovery rates (FDR) were estimated using a concatenated target-decoy 1 database [27] . For the estimation of the protein abundance ratio, the intensities of 2 iTRAQ reporter ions for each MS/MS spectra were extracted from ProteinPilot and the 3 sum ratio for each protein was calculated across the spectra matched to the 4 corresponding peptides. Data were normalized for loading error by bias corrections 5 using ProteinPilot. The statistical significance of the differences between the means for 6 each group (R vs. NR) was determined on the transformed data (arc sin hyperbolic) 7 using the two-tailed t-test. Threshold for significance was set at p < 0.05. A receiver 8 operation characteristic (ROC) curve analysis was performed for each protein to obtain 9 the area under curve (AUC). AUC was used as the summary statistic reflecting the 10 overall predictive accuracy of each protein [28] . A model or test with perfect 11 discriminatory ability will have an AUC of 1.0, while a model of random outcomes will 12 have an AUC of 0.5. Interactions and pathways of proteins with fold differences 13 between NR and R patients higher than 1.5 were analyzed with Ingenuity Pathway 14 Analysis (IPA) software (Ingenuity Systems, Redwood City, CA, USA). 15
Results and Discussion 17 Figure 1 shows the discovery-driven 8-plex iTRAQ workflow used in this study . 19 This workflow combines depletion of the highest abundance serum proteins, intensive 20 fractionation of the depleted serum, and MS/MS based identification and quantification 21 of the fractionated proteins. In the first step, sera were immunodepleted from the six 22 highest abundance proteins on a human MARS-6 spin column. Reproducibility and 23 protein recovery of this step were evaluated by 1-DE ( Figure 2 ) and by total protein 24 quantification. These analyses revealed uniform reduction of major protein bands and 25 compensatory increases in other bands of lower concentration together with significant 26 reduction of the total protein concentration. The mean protein recovery rate was 11.5%, 27 which is in agreement with the column's manufacturer specifications. Subsequent MS 28 analysis showed that this depletion step was effective because our protocol allowed the 29 identification with strict criteria (at least 2 peptides and 95% confidence) of medium 30 and low concentration proteins. Examples of identified proteins that are in the ng/mL 31 range according with the bibliography were hepatocyte growth factor activator, sex 32 hormone-binding globulin, alpha synuclein and retinoic acid receptor responder proteinrange. Since concentrations of the most abundant identified proteins are in the mg/mL 1 level, the workflow used in this study allowed the detection of serum proteins with a 2 dynamic range of up to 10 6 . A wide detection range is a necessary characteristic for 3 effective proteomic analysis of serum given the complexity and heterogeneity of this 4 biologic fluid. 5 6
Identification of serum proteins 7 8
The next steps involved trypsin digestion of the proteins, labeling of the 9 resulting peptides with the iTRAQ reagents, pooling samples in a single mix and 10 fractionation of the labeled peptides by SCX. The 27 initial fractions were collected and 11 their peptide complexity was determined by MALDI-TOF MS. Low complexity 12 fractions were pooled, given a total of 12 final fractions. These 12 fractions were 13 subjected to nanoHPLC-MS/MS in an Orbitrap Velos hybrid mass spectrometer. 14 Spectra were analyzed with ProteinPilot leading to the identification of 247 proteins 15 with at least 2 peptides (315 proteins with a single peptide) (Table S- The iTRAQ label ratios were used for relative quantification of 289 proteins, 7 237 of them with at least two peptides (Table S-2 in the Supplementary Material). 8
Comparison of protein abundance between responder and non-responder patients was 9 used to identify potential biomarkers for prediction of response to infliximab. Statistical 10 significance rather than fold difference is preferred for selection of proteins showing 11 differential abundance [39] . Therefore, we have used p-values < 0.05 from t-test 12 comparisons between the two groups of patients to discover 14 differential proteins 13 (Table 1 and (Table 1 and Table S-2  16 in the Supplementary Material). Each value of AUC can be interpreted as the 17 probability that the biomarker will rank a randomly chosen non-responder higher than a 18 randomly chosen responder [28] . The AUC value for a perfect test is 1.0, whereas the 19 value for a completely random test is 0.5. It is commonly accepted that tests with AUC 20 below 0.75 are unlikely to have interest for clinical use, whereas those with values over 21 0.75 could be of utility. All the differential proteins in our study were in this later group 22 with high predictive potential (Table 1) and H2 (ITIH2). Other four proteins in this pathway showed fold differences over 1.5 21 but were not significantly different: C8 beta, C8 alpha, C5 and complement factor H-22 related protein 3 (CFHR3). C4B is one of the two isotypes of C4, each of them encoded 23 by a different gene. Upon secretion, the C4 molecules are cleaved in three chains that 24 remain together as a trimer. The classic and the lectin complement activation pathways 25 include cleavage of the C4 alpha chain, which we have found different, into the C4a 26 anaphylotoxin and C4b, which continues with the activation cascade. The different 27 complement activation pathways converge in C3, whose activation is followed by the 28 cleavage of C5 in C5a, another anaphylotoxin, and C5b, which initiates the membrane 29 attack complex. This complex is the effector cytolytic endproduct of the complement 30 system and includes, among others, complement factors C5b and C8. The latter is made 31 of three subunits encoded in separated genes: C8 alpha, beta and gamma. CFHR4 is a 32 member of the CFH family that has recently been identified as promoting complementsame family that seems to be involved in regulation of the complement system by 1 inhibiting the activation of C3 [64] . MASP2, in turn, is a serum protease that activates 2 the lectin pathway via the cleavage of C4 and C2 [65] . Finally, the inter alpha trypsin 3 inhibitor (IαI) complex is made of two heavy chains ITIH1 and ITIH2 plus bikunin, and 4 it is a broad spectrum proteinase inhibitor. Among its many targets, it inhibits the early 5 phases of complement activation by the three pathways: classic, alternative and lectin 6
[66]. All these differential proteins related to complement can have a role in RA, since 7 the complement system is activated in the inflamed joints of patients with RA. This 8 activation state has been shown by the relative consumption of C3 and C4 in the 9 synovial fluid together with increased concentrations of C5a and the membrane attack 10 complex [67]. The higher abundance of all these proteins in the non-responder patients 11 makes it tempting to propose that this subset of patients is characterized by more 12 complement activation. However, this interpretation should be very cautious because 13 regulation of the complement system is mainly done at the activation levels and not at 14 the transcription level, and because ITIH1 and ITIH2 are inhibitors of complement 15
activation. An additional element to consider is that many components of the 16 complement system are acute phase reactants and they could be increased as a 17 consequence of inflammation [68] . 18
Other differential proteins in our results were also part of the acute phase showed a non-significant excess in the responder group (fold differences 0.8 and 0.65, 8 respectively). Therefore, we cannot exclude the possibility that the higher abundance of 9 these proteins is due to specific mechanisms unrelated with the intensity of 10 inflammation. 11
Finally, gelsolin (GSN) is a protein that does not fit in any of the previous 12 groups. In blood, it contributes to limit inflammatory responses by acting as a scavenger 13 The only previous study with similar aims has been already mentioned [8] . It 20 identified six potential proteins that were different between the non-responder and 21 responder RA patients treated with infliximab. These proteins showed AUC ranging 22 from 0.761 to 0.846, but not statistical tests or fold differences were reported. Five of 23 them were more abundant in the non-responder group and only one in the responder 24 patients, which is a direction of differences similar to our findings. Four of the proteins 25
were not further characterized because the authors used SELDI-TOF-MS and needed 26 purification for identification. The two identified proteins were also present in our 27 analysis. Platelet factor 4 was more abundant in the non-responder patients in both 28 studies (fold difference NR/R = 1.39; AUC = 0.81 in our samples), but the difference 29 was not significant in our analysis (P = 0.2). It has been also highlighted as a biomarker 30 for prediction of response to infliximab in a Crohn's disease study showing also higher 31 concentration in the non-reponder patients [80] . Therefore, platelet factor 4 seems a 32 good candidate biomarker although it did not came in the top list of our study. Theabundant in the non-responder patients in our study, as already discussed, whereas it 1 was more abundant in responder patients than in non-responder ones in Trocmé et al. 2 [8] . This discordant result serves us to remind that all these results need to be replicated 3 in new studies because of the exploratory nature of the previous and the current studies. 4
5

Conclusions 6 7
This report is the first label-based quantitative proteomics study aimed at 8 discovering potential serum biomarkers for prediction of response to biologics in RA. 9
The results have been encouraging in several respects: the number of identified proteins, 10 the dynamic range of concentrations they covered, and the number of differential 11 proteins between the two groups compared. The panel of differential proteins needs 12 further verification and clinical validation, but already it has been possible to notice that 13 most of these proteins are known to be related with important processes in RA and 14 many of them are known to show altered levels or function related with RA or chronic 15 inflammation. Therefore, we expect that they will help establish approaches to classify 16 RA patients as responders and non-responders to infliximab before the beginning of the 17 treatment, in order to treat anticipated non-responders with an alternative drug. 
